The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.

Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for ...

The novel drug reduces the need for burdensome phlebotomy and also addresses fatigue, thereby improving quality of life for ...

Adding rusfertide to standard care can reduce the need for phlebotomy and improve symptoms in patients with polycythemia vera who require frequent phlebotomies, data suggest.

Panelists discuss how risk stratification, symptom burden, and splenomegaly guide treatment decisions for a 68-year-old woman with intermediate-risk myelofibrosis who isn’t interested in transplant.

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet ...

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the ...